Russell Investments Group Ltd. Acquires 105,471 Shares of Enliven Therapeutics, Inc. $ELVN

Key Points

• Russell Investments Group Ltd. significantly increased its stake in Enliven Therapeutics, raising its position by over 148,500% during the first quarter, owning approximately 105,542 shares worth $2,077,000.
• Insiders at Enliven Therapeutics sold a total of 115,984 shares valued at approximately $2.4 million over the last 90 days, with both the CEO and another insider reporting ownership decreases of around 1.3% after their respective sales.
• Equities research analysts remain optimistic about Enliven Therapeutics, with several raising their target prices for the stock, leading to an average target of $41.20 and a general rating of "Buy."

Russell Investments Group Ltd. grew its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN - Free Report) by 148,550.7% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 105,542 shares of the company's stock after purchasing an additional 105,471 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.22% of Enliven Therapeutics worth $2,077,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of ELVN. Polar Capital Holdings Plc raised its stake in shares of Enliven Therapeutics by 267.6% during the 4th quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company's stock worth $53,768,000 after purchasing an additional 1,739,668 shares during the period. Janus Henderson Group PLC raised its stake in shares of Enliven Therapeutics by 27.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company's stock worth $30,001,000 after purchasing an additional 290,153 shares during the period. Boxer Capital Management LLC bought a new stake in shares of Enliven Therapeutics during the 4th quarter worth $15,106,000. Lord Abbett & CO. LLC raised its stake in shares of Enliven Therapeutics by 20.3% during the 4th quarter. Lord Abbett & CO. LLC now owns 386,211 shares of the company's stock worth $8,690,000 after purchasing an additional 65,156 shares during the period. Finally, Northern Trust Corp raised its holdings in shares of Enliven Therapeutics by 8.9% in the 4th quarter. Northern Trust Corp now owns 331,500 shares of the company's stock worth $7,459,000 after purchasing an additional 27,104 shares during the period. Institutional investors own 95.08% of the company's stock.

Insider Activity at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 6,667 shares of Enliven Therapeutics stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $18.24, for a total transaction of $121,606.08. Following the completion of the sale, the chief operating officer directly owned 289,975 shares in the company, valued at $5,289,144. The trade was a 2.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, August 27th. The shares were sold at an average price of $20.63, for a total transaction of $67,047.50. Following the sale, the chief financial officer owned 23,000 shares of the company's stock, valued at approximately $474,490. The trade was a 12.38% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 119,234 shares of company stock valued at $2,486,831. Company insiders own 25.90% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. HC Wainwright lifted their price target on shares of Enliven Therapeutics from $40.00 to $48.00 and gave the stock a "buy" rating in a report on Wednesday, July 2nd. The Goldman Sachs Group assumed coverage on shares of Enliven Therapeutics in a report on Monday, June 16th. They issued a "buy" rating and a $37.00 price target on the stock. Robert W. Baird lifted their price target on shares of Enliven Therapeutics from $40.00 to $52.00 and gave the stock an "outperform" rating in a report on Monday, June 16th. Finally, Jones Trading lowered their price target on shares of Enliven Therapeutics from $36.00 to $27.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $41.20.

Enliven Therapeutics Stock Performance

Enliven Therapeutics stock traded down $0.09 during midday trading on Friday, reaching $20.27. 589,226 shares of the stock were exchanged, compared to its average volume of 424,153. The company's fifty day moving average is $20.45 and its 200-day moving average is $19.78. The firm has a market cap of $1.20 billion, a PE ratio of -10.14 and a beta of 0.88. Enliven Therapeutics, Inc. has a 52 week low of $13.30 and a 52 week high of $30.03.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its earnings results on Wednesday, August 13th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.04. On average, sell-side analysts anticipate that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.